The PennZone

  • Home
  • Business
  • Real Estate
  • Travel
  • Health
  • Technology
  • Non-profit
  • Construction
  • Legal

Myonex Launches CTRx Europe, Central Pharmacy Network
The PennZone/10202189

Trending...
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Don't Get Burned by High Heater Prices in Philly This Winter!
HORSHAM, Pa.--(BUSINESS WIRE)--Myonex, a leading global clinical trial supply company, announces the launch of the first and only on-demand local drug sourcing in Europe. Built on a successful North American program, CTRx Europe offers significant benefits for trial sponsors, sites, and patients alike.

"With the growth of our CTRx service in North America, clients have been asking us to develop the same solution for them in Europe. Our new CTRx Europe solution is a game-changer for clinical sites in Europe," said James Lovett, Chief Executive Officer at Myonex. "Our solution will offer support for sites to source local drug for local patients, in individual European countries. Sponsors can remove overage and eliminate costs associated with up-front bulk comparator purchases, inventory management, and expired drugs. The program has delivered tremendous results in the United States and Canada, and we are pleased to be able to offer similar flexibility and savings in Europe."

More on The PennZone
  • Tri-State Area Entrepreneur Launches K-Chris: A Premium Digital Destination for Luxury Fragrances
  • Why One American Manufacturer Builds BBQ Smokers to Aerospace Standards
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • ZRCalc™ Cinema Card Calculator Now Available for Nikon ZR Shooters
  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy

Through its partnerships with central dispensing pharmacies in major European markets, Myonex can offer on-demand local sourcing. The CTRx solution provides sponsors with in-country local pricing and access to key oncology and other specialty medications and hospital lines. Sites need less storage space and fewer resources, so they can accommodate more trials. Sponsors can track dispensing via a secure, GDPR-compliant portal, and sites can request orders online.

Myonex's CTRx solution supports traditional, decentralized, and hybrid trials. In processes tailored to meet local regulations, both sponsor investigational medicinal products and commercial drugs, as well as ancillary items, can be delivered directly to the clinical site, central nursing center, a nurse, or even to the patient's home.

"The direct-to-patient offering makes adherence easier," said Samit Bhatt, Senior Director, Clinical Trial Patient Solutions, at Myonex. "And because our local partners serve local markets, logistics costs per patient and site shipment are lower, and sponsors can see significantly improved study start-up time."

More on The PennZone
  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
  • Author Jeff Bogle to Host Street Cats Mediterranean Cruise Featuring Cat Behaviorist Molly DeVoss
  • Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week

CTRx Europe is part of an end-to-end suite of clinical trial supply solutions from Myonex that also includes expanded packaging and labeling capabilities; warehousing, storage, and distribution; project management and more. For information, email globalsales@myonex.com.

About Myonex
Myonex
is a leading global clinical trial supply company with more than 30 years of experience supporting sponsors that range from Big Pharma to small biotech, as well as CROs, and other service providers. Its four unique services—sourcing, packaging/labeling, ancillaries and patient solutions—work together to create flexibility, improve effectiveness, increase efficiency and eliminate waste. The company problem-solves and tailors solutions to the specific requirements and complexities of each trial, and sponsors and CROs benefit from the simplicity of having a single vendor that can provide an optimized, integrated clinical trial supply strategy that saves time and money. Learn more at www.myonex.com.

Contacts

Maryanne Walsh
+1 267-307-0876
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Brain Drain Unlimited Strengthens Legal Advocacy with Advanced Training from Villanova University
  • Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Pallet Company Partners with Internet Marketing Company
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
  • Don't Get Burned by High Heater Prices in Philly This Winter!
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
  • Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Angels Of Dirt Premieres on Youtube, Announces Paige Keck Helmet Sponsorship for 2026 Season
  • Still Using Ice? FrostSkin Reinvents Hydration

Popular on PennZone

  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • NOW OPEN - New Single Family Home Community in Manalapan
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
  • 2025 Top Lawyers - ELA Awards by Expert Law Attorneys
  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors

Similar on PennZone

  • When Representation No Longer Reflects the District — Why I'm Voting for Pete Verbica
  • Off The Hook YS (NY SE: OTH) Executes Transformational Apex Acquisition, Creating Vertically Integrated Marine Powerhouse with $60M Inventory Capacity
  • Tri-State Area Entrepreneur Launches K-Chris: A Premium Digital Destination for Luxury Fragrances
  • Why One American Manufacturer Builds BBQ Smokers to Aerospace Standards
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us